is mounjaro a glp 1 receptor agonist Understanding GLP-1 agonists and their impact on drug discovery Mounjaro (GLP-1 Receptor Agonists) Overview

Novo already sells an oral semaglutide for type 2 diabetes, Rybelsus

1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

Using it off-label for weight loss would require much higher doses than it is currently approved for and it would not be cost effective

Fact : In July 2023, the European Medicines Agency began reviewing reports of patients causing self-harm or having suicidal ideation after taking weight-loss drugs that contain semaglutide

Easier access: With availability at tens of thousands of U.S

57% Reduction in Drinks Patients taking low-dose semaglutide experienced a 57% overall reduction in the number of drinks consumed per drinking day